株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の関節リウマチ薬/治療法の市場規模調査:分子タイプ、販売チャネル別(処方、店頭販売(OTC))、および地域別予測

Global Rheumatoid Arthritis Drugs/Therapeutics Market Size study, by Molecule Type (Biopharmaceuticals, Pharmaceuticals), by Sales Channel (Prescription, Over the Counter (OTC)) and Regional Forecasts 2019-2026

発行 Bizwit Research & Consulting LLP 商品コード 876669
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
世界の関節リウマチ薬/治療法の市場規模調査:分子タイプ、販売チャネル別(処方、店頭販売(OTC))、および地域別予測 Global Rheumatoid Arthritis Drugs/Therapeutics Market Size study, by Molecule Type (Biopharmaceuticals, Pharmaceuticals), by Sales Channel (Prescription, Over the Counter (OTC)) and Regional Forecasts 2019-2026
出版日: 2019年06月25日 ページ情報: 英文
概要

当レポートでは世界の関節リウマチ薬/治療法市場について調査しており、市場機会、分子タイプ・販売チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

第1章 エグゼクティブサマリー

  • 市場のスナップショット
  • 主要傾向
  • 全体およびセグメント別市場予測
    • 分子タイプ別
    • 販売チャネル別
    • 地域別
  • 調査方法
  • 調査の前提条件

第2章 関節リウマチ薬/治療法市場の定義と範囲

  • 研究の目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 研究のために考慮された年
  • 為替レート

第3章 関節リウマチ薬/治療法市場のダイナミクス

  • シーソー分析
    • 市場成長要因
    • 市場の課題
    • 市場機会

第4章 関節リウマチ薬/治療法市場業界分析

  • ポーターのファイブフォース分析
    • バイヤーの交渉力
    • サプライヤーの交渉力
    • 新規参入の脅威
    • 代用品の脅威
    • 業界内の競争
    • ポーターのファイブフォース分析への未来的アプローチ
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
  • 主な購入基準(オンデマンド)
  • 規制の枠組み(オンデマンド)
  • 投資/導入シナリオ(オンデマンド)
  • アナリストの提言と結論

第5章 関節リウマチ薬/治療法市場:分子タイプ別

  • 市場のスナップショット
  • 市場実績 - ポテンシャルモデル
  • 主要市場参入企業
  • 関節リウマチ薬/治療薬市場、サブセグメント分析
    • バイオ医薬品
    • 医薬品

第6章 関節リウマチ薬/治療法市場:販売チャネル別

  • 市場のスナップショット
  • 市場実績 - ポテンシャルモデル
  • 主要市場参入企業
  • 関節リウマチ薬/治療法市場、サブセグメント分析
    • 処方
    • 店頭販売(OTC)

第7章 地域分析別関節リウマチ薬/治療法市場

  • 関節リウマチ薬/治療法市場、地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • その他の欧州
  • アジア
    • 中国
    • インド
    • 日本
    • その他のアジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • その他の世界の地域
    • 南米
    • 中東およびアフリカ

第8章 競合情勢

  • 企業の市場シェア(データの入手可能性別)
  • トップ市場戦略
  • 企業プロファイル
    • Abb Vie
    • Amgen Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Novartis International AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB S.A.

第9章 調査方法

  • 調査方法
    • データマイニング
    • 分析
    • 市場予測
    • 検証
    • 出版
    • 調査の前提条件
図表

List of Tables

List of Tables

  • TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET
  • TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET
  • TABLE 3. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, REPORT SCOPE
  • TABLE 4. YEARS CONSIDERED FOR THE STUDY
  • TABLE 5. EXCHANGE RATES CONSIDERED
  • TABLE 6. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
  • TABLE 7. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY MOLECULE TYPE 2016-2026 (USD BILLION)
  • TABLE 8. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SALES CHANNEL 2016-2026 (USD BILLION)
  • TABLE 9. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 10. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 11. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 12. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 13. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 14. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 15. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 16. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 17. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 18. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 19. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 20. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 21. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 22. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 23. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 24. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 25. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 26. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 27. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 28. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 29. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 30. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 31. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 32. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 33. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 34. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 35. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 36. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 37. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 38. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 39. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 40. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 41. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 42. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 43. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 44. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 45. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 46. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 47. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 48. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 49. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 50. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 51. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 52. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 53. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 54. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 55. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 56. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 57. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 58. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 59. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 60. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 61. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 62. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 63. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 64. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 65. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 66. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 67. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 68. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 69. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 70. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 71. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 72. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 73. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 74. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 75. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 76. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 77. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 78. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 79. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 80. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 81. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 82. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 83. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 84. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 85. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 86. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 87. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 88. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 89. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 90. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 91. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 92. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 93. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 94. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 95. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 96. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 97. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 98. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 99. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 100. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 101. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 102. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 103. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 104. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 105. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 106. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 107. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 108. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 109. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

List of Figures

List of Figures

  • FIG 1. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, RESEARCH METHODOLOGY
  • FIG 2. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, MARKET ESTIMATION TECHNIQUES
  • FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
  • FIG 4. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, KEY TRENDS 2017
  • FIG 5. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, GROWTH PROSPECTS 2018-2026
  • FIG 6. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, PORTERS 5 FORCE MODEL
  • FIG 7. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, PEST ANALYSIS
  • FIG 8. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, VALUE CHAIN ANALYSIS
  • FIG 9. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 10. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 11. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 12. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 13. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 14. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 15. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 16. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 17. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 18. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 19. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 20. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 21. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 22. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 23. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 24. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 25. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 26. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 27. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 28. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 29. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 30. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 31. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, REGIONAL SNAPSHOT 2016 & 2026
  • FIG 32. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 33. EUROPE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 34. ASIA PACIFIC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 35. LATIN AMERICA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 36. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, COMPANY MARKET SHARE ANALYSIS (2017)
目次

Global Rheumatoid Arthritis Drugs/Therapeutics Market valued approximately USD 22.14 billion in 2018 is anticipated to grow with a healthy growth rate of more than 4.50% over the forecast period 2019-2026. The Rheumatoid Arthritis Drugs/Therapeutics Market is continuously growing in the global scenario at significant pace. Rheumatoid arthritis (RA) is the most common type of autoimmune chronic disease that causes joint pain, swelling and stiffness in joint and even loss of joint function. To overcome this diseases various medications are introduced such as disease-modifying anti-rheumatic drugs (DMARDs), biological response modifiers (a type of DMARD), glucocorticoids, analgesics (painkillers) and nonsteroidal anti-inflammatory medications (NSAIDs). DMARDs have significantly enhanced the quality of life for numerous people suffering from rheumatoid arthritis. Rising geriatric population worldwide, increasing prevalence of rheumatoid and structured reimbursement & regulatory framework are the substantial driving factors of the market during the forecast period. Additionally, increasing awareness regarding diseases remittances therapies and growing healthcare expenditure are another factor that impelling the demand of rheumatoid arthritis drugs across the globe. Moreover, rise in need of Rheumatoid Arthritis Drugs/Therapeutics due to increasing prevalence of disease is the factors that likely to create numerous opportunity in the near future. However, patient expiration of many leading drugs is one of the major factors that limiting the growth of the market during the forecast period.

The regional analysis of Global Rheumatoid Arthritis Drugs/Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising awareness associated with the disease, growing healthcare expenditure and high adoption of biopharmaceuticals for the treatment in the region. Europe is estimated to grow at stable growth rate in the global Rheumatoid Arthritis Drugs/Therapeutics market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing adoption of rheumatoid arthritis drugs in the region.

The major market player included in this report are:

Abb Vie

Amgen Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb

F. Hoffmann-La Roche AG

Johnson & Johnson

Novartis International AG

Pfizer Inc.

Regeneron Pharmaceuticals Inc.

UCB S.A.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Molecule Type:

Biopharmaceuticals

Pharmaceuticals

By Sales Channel:

Prescription

Over the Counter (OTC)

By Regions:

Furthermore, years considered for the study are as follows:

Historical year - 2016, 2017

Base year - 2018

Forecast period - 2019 to 2026

Target Audience of the Global Rheumatoid Arthritis Drugs/Therapeutics Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Key Trends
  • 1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
    • 1.3.1. Rheumatoid Arthritis Drugs/Therapeutics Market, by Molecule Type, 2016-2026 (USD Billion)
    • 1.3.2. Rheumatoid Arthritis Drugs/Therapeutics Market, by Sales Channel, 2016-2026 (USD Billion)
    • 1.3.3. Rheumatoid Arthritis Drugs/Therapeutics Market, by Region, 2016-2026 (USD Billion)
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Rheumatoid Arthritis Drugs/Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Rheumatoid Arthritis Drugs/Therapeutics Market Dynamics

  • 3.1. See Saw Analysis
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Rheumatoid Arthritis Drugs/Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Buyers
    • 4.1.2. Bargaining Power of Suppliers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.2. PEST Analysis
    • 4.2.1. Political Scenario
    • 4.2.2. Economic Scenario
    • 4.2.3. Social Scenario
    • 4.2.4. Technological Scenario
  • 4.3. Key Buying Criteria (On Demand)
  • 4.4. Regulatory Framework (On Demand)
  • 4.5. Investment Vs Adoption Scenario (On Demand)
  • 4.6. Analyst Recommendation & Conclusion

Chapter 5. Rheumatoid Arthritis Drugs/Therapeutics Market, by Molecule Type

  • 5.1. Market Snapshot
  • 5.2. Market Performance - Potential Model
  • 5.3. Key Market Players
  • 5.4. Rheumatoid Arthritis Drugs/Therapeutics Market, Sub Segment Analysis
    • 5.4.1. Biopharmaceuticals
      • 5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 5.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 5.4.2. Pharmaceuticals
      • 5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 6. Rheumatoid Arthritis Drugs/Therapeutics Market, by Sales Channel

  • 6.1. Market Snapshot
  • 6.2. Market Performance - Potential Model
  • 6.3. Key Market Players
  • 6.4. Rheumatoid Arthritis Drugs/Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Prescription
      • 6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 6.4.2. Over the Counter (OTC)
      • 6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 7. Rheumatoid Arthritis Drugs/Therapeutics Market, by Regional Analysis

  • 7.1. Rheumatoid Arthritis Drugs/Therapeutics Market, Regional Market Snapshot (2016-2026)
  • 7.2. North America Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.2.1. U.S.
      • 7.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.1.3. Sales Channels breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.2.2. Canada
      • 7.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.3. Europe Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.3.1. U.K.
      • 7.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.3.2. Germany
      • 7.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.3.3. Rest of Europe
      • 7.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.3.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.3.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.4. Asia Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.4.1. China
      • 7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.4.2. India
      • 7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.4.3. Japan
      • 7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.3.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.3.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.4.4. Rest of Asia Pacific
      • 7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.4.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.4.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.5. Latin America Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.5.1. Brazil
      • 7.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.5.2. Mexico
      • 7.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.6. Rest of The World
    • 7.6.1. South America
      • 7.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.6.2. Middle East and Africa
      • 7.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 8. Competitive Intelligence

  • 8.1. Company Market Share (Subject to Data Availability)
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Abb Vie
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial (Subject to Data Availability)
      • 8.3.1.3. Summary
      • 8.3.1.4. Recent Developments
    • 8.3.2. Amgen Inc.
    • 8.3.3. Boehringer Ingelheim GmbH
    • 8.3.4. Bristol-Myers Squibb
    • 8.3.5. F. Hoffmann-La Roche AG
    • 8.3.6. Johnson & Johnson
    • 8.3.7. Novartis International AG
    • 8.3.8. Pfizer Inc.
    • 8.3.9. Regeneron Pharmaceuticals Inc.
    • 8.3.10. UCB S.A.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
    • 9.1.6. Research Assumption
Back to Top